Regen BioPharma Files Immuno-Oncology Patent Application

Regen BioPharma has announced the filing of a US patent application covering a newly discovered synergy between inhibition of NR2F6 and cannabidiol (CBD). The new data demonstrates enhanced ability to reduce cancer growth in an efficacious manner while appearing not to induce any form of toxicity.

In a series of experiments, Regen collaborators extracted immune system cells from mice called 'dendritic cells'. These cells where treated with cannabidiol, which caused suppression of their ability to activate cancer killing immune T cells. Surprisingly, in the presence of NR2F6 inhibition, the cannabidiol actually increased ability to activate T cells. The Company currently possesses small molecule inhibitors of NR2F6, as well as various genetic means such as inducers of RNA Interference, to block expression of NR2F6.

"Numerous studies have shown the NR2F6 is critically involved in the ability of cancer cells to resist death, as well as to possess other pathogenic properties," Thomas Ichim, PhD, co-inventor of the patent and a senior scientific consultant to Regen BioPharma said. "It is very interesting that NR2F6 also acts as an 'immunological checkpoint' in that it prevents immune system activation. By using small molecules, as well as RNA interference, we are able to de-repress the immune system in cancer models. What is striking about the data disclosed today is that inhibition of NR2F6 not only increases activity of dendritic cells, but also changes cannabidiol from an immune inhibitor to an immune stimulator."

"Checkpoint inhibitors are a new class of drugs, which include Ipilimumab (Yervoy® Bristol Myers Squibb, 2018 estimated sales of $1.5 Billion), and Pembrolizumab (Keytruda® Merck, 2017 sales of $3.4 Billion)," Chairman and CEO David Koos said. "Current checkpoint inhibitors act to augment immune responses but do not have direct anticancer effects. By creating approaches to inhibit NR2F6, the Company aims to develop a new class of checkpoint inhibitors that concurrently block tumor growth while enhancing the immune system."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com